Joseph Catanzaro
Stock Analyst at Piper Sandler
(1.94)
# 3,158
Out of 4,984 analysts
97
Total ratings
36.71%
Success rate
-6.69%
Average return
Main Sectors:
Stocks Rated by Joseph Catanzaro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IBRX ImmunityBio | Upgrades: Overweight | $4.25 → $5 | $2.81 | +77.94% | 5 | May 20, 2025 | |
| CTMX CytomX Therapeutics | Maintains: Overweight | $2.5 → $5 | $1.96 | +155.10% | 5 | May 15, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Neutral | $7.5 → $6 | $2.30 | +160.87% | 10 | Feb 28, 2025 | |
| SDGR Schrödinger | Maintains: Overweight | $50 → $45 | $19.11 | +135.48% | 3 | Feb 27, 2025 | |
| MRUS Merus | Initiates: Overweight | $84 | $66.90 | +25.56% | 1 | Feb 13, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $105 → $110 | $110.86 | -0.78% | 5 | Feb 12, 2025 | |
| EXEL Exelixis | Maintains: Overweight | $37 → $38 | $39.14 | -2.91% | 4 | Feb 12, 2025 | |
| KROS Keros Therapeutics | Maintains: Overweight | $40 → $15 | $15.80 | -5.06% | 3 | Jan 17, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $52 → $53 | $75.85 | -30.13% | 9 | Jan 10, 2025 | |
| CRDF Cardiff Oncology | Maintains: Overweight | $7 → $10 | $2.00 | +400.00% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $57 → $70 | $44.70 | +56.60% | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $2 | $0.19 | +934.66% | 2 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $19 | $2.02 | +840.59% | 5 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $19 | $6.00 | +216.67% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $15 | $3.17 | +373.19% | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 | $41.29 | -12.81% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 | $7.11 | +462.59% | 5 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 | $12.44 | +20.63% | 4 | Jun 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 | $8.44 | +314.69% | 1 | Jun 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $4.5 | $0.85 | +430.79% | 1 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $30 | $1.55 | +1,835.48% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.15 | +1,639.13% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $10 | $3.72 | +168.82% | 4 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $7.35 | +144.90% | 1 | Feb 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $25 | $1.74 | +1,336.78% | 3 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $1.75 | $5.95 | -70.59% | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $20.07 | -0.35% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $1.5 | $1.61 | -6.83% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $240 → $200 | $8.90 | +2,147.19% | 2 | Mar 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $7.33 | +377.49% | 1 | Jun 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $0.99 | +5,931.36% | 1 | Mar 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $18 | $2.69 | +569.14% | 3 | Apr 7, 2020 |
ImmunityBio
May 20, 2025
Upgrades: Overweight
Price Target: $4.25 → $5
Current: $2.81
Upside: +77.94%
CytomX Therapeutics
May 15, 2025
Maintains: Overweight
Price Target: $2.5 → $5
Current: $1.96
Upside: +155.10%
Iovance Biotherapeutics
Feb 28, 2025
Maintains: Neutral
Price Target: $7.5 → $6
Current: $2.30
Upside: +160.87%
Schrödinger
Feb 27, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $19.11
Upside: +135.48%
Merus
Feb 13, 2025
Initiates: Overweight
Price Target: $84
Current: $66.90
Upside: +25.56%
Gilead Sciences
Feb 12, 2025
Maintains: Overweight
Price Target: $105 → $110
Current: $110.86
Upside: -0.78%
Exelixis
Feb 12, 2025
Maintains: Overweight
Price Target: $37 → $38
Current: $39.14
Upside: -2.91%
Keros Therapeutics
Jan 17, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $15.80
Upside: -5.06%
Halozyme Therapeutics
Jan 10, 2025
Maintains: Neutral
Price Target: $52 → $53
Current: $75.85
Upside: -30.13%
Cardiff Oncology
Dec 13, 2024
Maintains: Overweight
Price Target: $7 → $10
Current: $2.00
Upside: +400.00%
Nov 7, 2024
Maintains: Overweight
Price Target: $57 → $70
Current: $44.70
Upside: +56.60%
Nov 4, 2024
Downgrades: Neutral
Price Target: $15 → $2
Current: $0.19
Upside: +934.66%
Oct 31, 2024
Maintains: Overweight
Price Target: $10 → $19
Current: $2.02
Upside: +840.59%
Oct 7, 2024
Initiates: Overweight
Price Target: $19
Current: $6.00
Upside: +216.67%
Sep 23, 2024
Maintains: Overweight
Price Target: $12 → $15
Current: $3.17
Upside: +373.19%
Aug 15, 2024
Maintains: Overweight
Price Target: $36
Current: $41.29
Upside: -12.81%
Jul 8, 2024
Maintains: Overweight
Price Target: $40
Current: $7.11
Upside: +462.59%
Jun 14, 2024
Maintains: Overweight
Price Target: $15
Current: $12.44
Upside: +20.63%
Jun 5, 2024
Maintains: Overweight
Price Target: $35
Current: $8.44
Upside: +314.69%
May 16, 2024
Initiates: Overweight
Price Target: $4.5
Current: $0.85
Upside: +430.79%
Apr 25, 2024
Maintains: Overweight
Price Target: $26 → $30
Current: $1.55
Upside: +1,835.48%
Apr 22, 2024
Initiates: Overweight
Price Target: $20
Current: $1.15
Upside: +1,639.13%
Mar 18, 2024
Maintains: Overweight
Price Target: $15 → $10
Current: $3.72
Upside: +168.82%
Feb 12, 2024
Initiates: Overweight
Price Target: $18
Current: $7.35
Upside: +144.90%
Oct 16, 2023
Maintains: Overweight
Price Target: $30 → $25
Current: $1.74
Upside: +1,336.78%
May 23, 2023
Downgrades: Neutral
Price Target: $15 → $1.75
Current: $5.95
Upside: -70.59%
Dec 20, 2022
Maintains: Overweight
Price Target: $18 → $20
Current: $20.07
Upside: -0.35%
May 5, 2022
Downgrades: Neutral
Price Target: $25 → $1.5
Current: $1.61
Upside: -6.83%
Mar 10, 2022
Maintains: Overweight
Price Target: $240 → $200
Current: $8.90
Upside: +2,147.19%
Jun 21, 2021
Initiates: Overweight
Price Target: $35
Current: $7.33
Upside: +377.49%
Mar 25, 2021
Initiates: Overweight
Price Target: $60
Current: $0.99
Upside: +5,931.36%
Apr 7, 2020
Maintains: Overweight
Price Target: $28 → $18
Current: $2.69
Upside: +569.14%